Send to

Choose Destination
Curr Opin Immunol. 2016 Jun;40:14-23. doi: 10.1016/j.coi.2016.02.008. Epub 2016 Mar 7.

New developments for antibody-drug conjugate-based therapeutic approaches.

Author information

Genmab, Yalelaan 60, 3584 CM Utrecht, The Netherlands. Electronic address:
ImmunoGen, Inc., 830 Winter Street, Waltham, MA 02451, United States.


The clinical success of Adcetris(®) (brentuximab vedotin) and Kadcyla(®) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center